word count 264 Abstract Background Remission and recovery rates for people with a First Episode Psychosis (FEP) remain uncertain.
Introduction
Psychotic disorders are marked by heterogeneity in terms of clinical presentation and outcome. 1 Historically, schizophrenia was conceptualised as a chronic, progressive deteriorating condition. However, there is increasing recognition that people with schizophrenia can experience symptomatic improvements and regain a degree of social and occupational functioning. 2 Over the past 20 years there has been an increased focus on specialist early intervention services for first episode psychosis (FEP). 3, 4 However, it remains unclear what the outcomes are for people with FEP (including those with first episode schizophrenia (FES) in terms of remission and recovery.
To our knowledge, only 3 systematic reviews and 2 meta-analyses have considered recovery or remission in FEP and/or schizophrenia. [5] [6] [7] [8] [9] The most recent systematic review and meta-analysis concluded that only 13.5% of schizophrenia patients met the criteria for recovery, though the follow up period is not given, and this review included both FES and multi episode schizophrenia patients. 9 Multi episode patients include those with more chronic or treatment resistant illnesses, who would by definition be expected to have lower recovery rates.
A systematic review in FEP identified 'good' outcomes for 42% of patients with psychosis and 31% of schizophrenia patients, 7 while a later review of remission in FEP identified an average remission rate of 40% (range 17%-78%). 6 These reviews in FEP have been limited by wide variety of outcome definitions used, 7 in keeping with a paucity of identified studies using standardized definitions of remission or recovery, a small number of included studies, 6 and no FEP review including a metaanalysis.
While naturalistic FEP outcome studies of increasing sophistication and duration have been published, [10] [11] [12] [13] the longer term outcomes for these patients in terms of remission and recovery rates remains uncertain. This deficiency in the literature is important, as, since the introduction of the Remission in Schizophrenia Working Group (RSWG) criteria for remission in 2005, many studies in FEP have sought to use the operationalized criteria for remission in schizophrenia. 14 We, therefore, conducted a systematic review and meta-analysis to assess pooled prevalence rates of remission and recovery in FEP and FES in longitudinal studies.
In addition, we sought to identify potential moderators of remission and recovery.
Finally, we sought to investigate if specific variables have an impact on remission and recovery proportions (e.g. narrow and broad remission and recovery definitions, duration of follow-up, region of study and the study year).
Our a priori hypotheses were the following: 1. A greater proportion of patients with FEP will meet criteria for remission and recovery in studies from the past twenty years compared to earlier studies.
2. Recovery will be less prevalent in samples with longer duration of follow-up compared with shorter follow-up.
3. Rates of remission and recovery will be lower with the use of narrow criteria for defining remission and recovery.
Methods
This systematic review was conducted in accord with the Meta-analysis of Observational Studies in Epidemiology guidelines 15 
and the Preferred Reporting
Items for Systematic Reviews and Meta-analyses standard. 16 
Inclusion criteria
We included studies of longitudinal observational design (both retrospective and prospective studies) in patients >16 years old (with no upper age limit) that fulfilled the following criteria: A) i) reporting remission rates and/or ii) recovery rates in people with a FEP (including FES and first episode affective psychosis) irrespective of clinical setting (inpatient, outpatient or mixed).
Remission has been operationalized in terms of symptomatic and/or functional improvement with a duration component. The use of the Remission in Schizophrenia Working Group (RSWG) criteria has become common over the past decade measuring both an improvement in symptoms and duration criteria (>6 months) for persistence of mild or absent symptoms. 14 For remission, we categorised remission criteria into broad and narrow criteria for defining remission. Those studies in which remission was defined by the RSWG criteria (composed of two dimensions, accounting for symptom severity (mild or absent) and a duration criterion of mild or absent symptoms of ≥6 months) or if defined as patients being asymptomatic & attaining pre-morbid functioning sustained for ≥6 months, were classified as narrow criteria for remission. Those studies which defined symptomatic remission, but not a duration were classified as broad criteria.
Recovery has been operationalised as a multidimensional concept, incorporating symptomatic, and functional improvement in social, occupational and educational domains, with a necessary duration component (>2 years). 9, 17, 18 For recovery, we mirrored the approach of Jääskeläinen et al., 2013, categorising those studies in which both clinical and functioning dimensions are operationally assessed, along with a duration of sustained improvement for ≥2 years. 9 We further analysed recovery in relation to those studies in which both clinical and level of functioning dimensions were assessed, but with a duration for sustained improvement of >1 year. We 
Search criteria
Two independent authors (JL, OA) searched PubMed, Medline, and Scopus without language restrictions from database inception until July 1, 2016. Key words used were "first episode psychosis" OR "early episode psychosis" OR "schizophrenia" OR "schiz*" AND "remission" OR "recovery" AND "outcome" OR "follow-up". Manual searches were also conducted using the reference lists from recovered articles and recent reviews. 6, 7, 9 
Data Extraction
Two authors (JL and OA) extracted all data, and any inconsistencies were resolved by consensus or by a third author (BS). One author (OA) extracted data using a predetermined data extraction form, which was subsequently validated by a second author (JL). The data extracted included first author, country, setting, population, study design (e.g. prospective, retrospective), participants included in the study (including mean age, % female), diagnostic classification method, method of assessment (e.g. face-face interviews, case records, or combination of both approaches), duration of untreated psychosis (DUP), socio-demographic characteristics of the sample employed in the study (e.g., % employed, single or in stable relationship at the study entry), baseline psychotic symptoms (mean scores), length of study follow up, participant loss at follow up, and criteria used to define remission and recovery. When studies reported on overlapping samples, details of the study with the longest follow up were included, or if this was unclear, studies with the largest study sample for each respective outcome were included. We included multi-site studies, and retained data for the entire cohort and not for individual sites.
Primary outcomes
The co-primary outcomes were the proportion of people with FEP who met the criteria for a) remission and b) recovery over the course of each study as defined above.
Statistical analysis
Due to the anticipated heterogeneity across studies, we conducted a random effects meta-analysis. The meta-analysis was conducted in the following sequence. First, we calculated the pooled prevalence rates of remission and recovery in FEP. Second, in order to account for attrition bias, we imputed a remission and recovery rate using the principle of worst case scenario assuming all people who dropped out did not have a favourable outcome. Third, we calculated the subgroup differences in remission and recovery according to whether a narrow or broad definition of remission or recovery was used, the first episode diagnosis category, the method used to assess remission and recovery (structured face-to-face assessment; structured assessment supplemented with clinical notes and/or interviews with parents; clinical records), duration of follow-up (categorised into three groups: 1-2 years; 2-6 years; >6 years based on ascending duration of follow-up (tertiles)), region of study, the study period (we selected the midpoint of the study period as the study year, and categorized this by adapting criteria proposed by Warner et al. 5 for recovery studies-pre 1975; 1976-1996; 1997-2016 ; and for remission studies-pre 1975; 1976-1996; 1997-2004; 2005-2016) , the study design, and the setting of the study at FEP (inpatient; community & early intervention services; and mixed in-and out-patient psychiatric services).
Fourth, we conducted meta-regression analyses to investigate potential moderators of remission and recovery (age, percentage of males, ethnicity, baseline psychotic symptoms (mean scores), relationship and employment status at first contact, DUP, duration of follow up, attrition rate and study year.
Publication bias was assessed with the funnel plot, Egger regression test, 19 and the "trim and fill" method. 20 Heterogeneity was measured with the Q statistic, yielding a chi-square and p-value, and the I2 statistic with scores above 50% and 75% indicating moderate and high heterogeneity. 21 Finally, descriptive statistical methods were used for the exploratory summary of study-reported correlates of remission and recovery based on patient-level data not available for study-level meta-regression analyses.
All analysis was conducted with Comprehensive Meta-Analysis software (CMA, Version 3) and STATA release 14 (STATACorp LP, USA).
Results

Search results and included participants
Our search yielded 3021 non-duplicated publications, which were considered at the title, and abstract level; 299 full texts were reviewed, of which 79 met inclusion criteria ( Figure 1 ). [10] [11] [12] [13] 
Meta-analysis of remission and recovery:
Rate of remission
The pooled rate of remission among 19,072 individuals with FEP was 57.9% (95% CI=52.7-62.9, Q=1536.3, p<0.001, N=60)(see Figure S1 in the online data supplement). The Begg-Mazumdar (Kendall's tau b=0.151, p=0.09) and Egger test (bias=0.98, 95% CI=-1.423.38, p=0.47) indicated no publication bias. A visual inspection of the funnel plot revealed that there was some asymmetry in the plot, and we adjusted for this asymmetry and potential missing studies (see FigureS1 in the online data supplement). The trim-and-fill method demonstrated that the prevalence of remission was unaltered when adjusted for potential missing studies. Restricting the analysis to studies which used the RSWG criteria for remission (N=25 studies, N=6,909 patients), the overall pooled prevalence remission rate was 56.9% (95% CI=48.9-64.5, Q=656.9, N=25 studies). Using the worst case scenario, the remission rate was 39.3% (95% CI=35.1-43.5, Q=1371, N=55 studies).
Subgroup analyses of remission rates
Full details of the proportion of people who experienced remission, together with heterogeneity and trim and fill analyses are summarized in Table 1 . Results of interest are briefly discussed below.
Insert table 1 here
For those studies with FES patients only, the pooled remission rate was 56.0% (95% CI=47.5-64.1, Q=378.50, N=25 studies), with an equivalent rate of 55.4% (95% CI=47.7-62.8, Q=1049.0, N=29 studies) for FEP patients; the pooled remission rate was higher in FE affective psychosis only patients (78.7%, 95% CI=63.9-88.5, Q=68.6, N=6 studies) compared to people with FES.
There were no differences in remission rates by the study period, duration of study follow up, study type or setting, or proportion of studies using narrow remission criteria. Remission rates were significantly higher in studies from Africa ( 
Meta regression of factors influencing remission rates
Full details of the moderators of remission are presented in Table 2 . Higher remission rates were associated with studies conducted in more recent years (β=0.04, 95% CI=0.01-0.08, p=0.018, R 2 =0.10).
Insert table 2 here
Rate of recovery
Full details of the proportion of people who are recovered, together with heterogeneity and trim and fill analyses are summarized in Table 3 .
Insert table 3 here
The pooled rate of recovery among 9,642 individuals with FEP was 37.9% (95% CI=30.0-46.5, Q=1450.8, N=35 studies, p=0.006) (see Figure S3 in the online data supplement). The Begg-Mazumdar (Kendall's tau b=-1.0, p=0.37) and Egger test (bias=2.32, 95% CI=-1.77 -6.42, p= 0.25) indicating no publication bias. A visual inspection of the funnel plot revealed that the plot was largely symmetric (see Figure   S4 in the online data supplement).The trim-and-fill method demonstrated that the prevalence of recovery was unaltered when adjusted for potential missing studies.
Assuming the worst case scenario technique, the pooled prevalence of recovery was 23.3% (95% CI=18.4-29.2, Q=1270, N=33 studies).
Subgroup analyses of recovery rates
For those studies using the narrowest recovery criteria, the recovery rate was 25 Following the trim and fill analysis the recovery rate from North America decreased slightly to 68.5% (95% CI=48.6-83.4); there was a slight increase in the recovery rate seen in studies from Europe to 26.3% (95% CI=16.6-38.9). There were no significant Equivalent rates of recovery were found in those with FEP (34.4%) and FES (30.3%) diagnoses. Those with a diagnosis of FE affective psychosis had a significantly increased pooled recovery rate (84.6%, 95% CI=64.0-94.4, Q=109.3, N=4 studies) compared to those with FEP (34.4% (95% CI: 25.2-44.9, Q=527.0, N=19 studies), and FES (30.3% (95% CI=19.7-43.6., Q=514.7, N=12 studies) (p=0.0031).
Meta regression of factors influencing recovery rates
Full details of the moderators of recovery are presented in supplementary table 3.
Briefly, the meta regression analyses showed that higher rates of recovery were moderated by White ethnicity (β=0.02, 95% CI=0.01-0.04, p=0.002, R 2 =0.41); whereas, lower rates of recovery were moderated by Asian ethnicity (β=-0.02, 95%CI=-0.04-0.00, p=0.019, R2=0.32) and a higher loss to attrition (or drop-out rates) (β=-0.04, 95%CI=-0.07--0.01, p=0.009, R 2 =0.21).
Discussion
This novel, large scale meta-analysis found that fifty-eight percent of FEP patients meet criteria for remission and 38% meet criteria for recovery over a mean of 5.5 and 7.2 years follow up respectively. Thirty percent of those with FES met the criteria for recovery. Our findings are particularly relevant given the previously reported lower rates of recovery in multi episode schizophrenia of 13%. 9 The average duration of follow up of 5.5 years in our remission sample and 7.2 years in our recovery cohort adds further weight to the significance of our findings.
Remission
Our findings for remission were remarkably stable and did not differ dependent on the use of more stringent criteria such as the RSWG (57%) or the use of broader criteria (59%). Our remission rate of 57% based on studies using the RSWG criteria, is higher than the rate of 40% identified in a systematic review from 2012. 6 Our study improves on this previous review by the inclusion of 25 studies using the RSWG criteria to define remission, as compared to 12 studies, and by having a longer average duration of follow up.
Few variables were found to be moderators of remission rates, and no patient level clinical or demographic variables were associated with remission. We identified that a more recent study period was associated with improved remission rates, perhaps reflecting the improved outcomes from FEP patients treated in dedicated early intervention services over the past two decades.
Recovery
Our identified rate of recovery of 38% in FEP is higher than previously identified rates of 13.5% and 11-33% in multi episode schizophrenia. 5, 9 Our imputed recovery rate of 23% based on the worst case scenario technique is equivalent to the recovery rate for those studies which defined recovery based on symptomatic and functional improvement sustained for more than 2 years. Further, this worst case scenario recovery rate of 23% remains higher than that identified in most recent review of One interesting finding is the significantly increased pooled prevalence of recovery identified in North America (Canada and USA) compared to all other regions. This regional variation in recovery was not accounted for by statistically significant differences in baseline clinical and demographic variables, or dropout rates. We identified that none of the North American studies used the more conservative twoyear criterion to define recovery, compared to 32% (N=8) of studies from other regions, and only 11% (N=1) of North American studies had a follow up of longer than 6 years, compared to 52% (N=13) from other regions, differences which trended towards significance, and which potentially impacted on the improved recovery rate from this region. This finding warrants further investigation. It may be related to differences in the types of patients with FEP who were enrolled in North America compared to other regions. There may be other service level confounds which we were unable to investigate, such as an increased proportion of studies in North America occurring in academic centres, in which the potential for more intensive and multimodal treatment approaches may have been available. However, we were unable to assess the effects of variable treatments by region which may have contributed to improved recovery rates in North America. Further, the influence of potential non-representative sampling in North America 97 could not be accounted for. However, the recovery rates for studies from North America remained higher compared to other regions across the study periods, suggesting that the findings may not be related to health service developments in that region over time.
We demonstrated for the first time in a large scale meta-analysis that recovery in FEP is not reduced with a longer duration of follow up. This finding, contrary to one of our hypotheses, was interesting, in that those with a follow up period greater than 6 years (32% recovery rate) and those with a 2-6 year follow up (32% recovery rate), had equivalent rates of recovery, indicating that the rate of recovery seen from 2-6 years, can be maintained for patients followed up beyond 6 years. This is in contrast to previous reviews that found an association between longer follow up duration and reductions in 'good' outcomes. 7, 8 If psychotic disorders, and more specifically schizophrenia are progressive disorders, then we might expect to see decreased recovery rates with longer periods of follow up. The fact that we have not identified any changes in recovery rates after the first two years of follow up indicates an absence of progressive deterioration. This suggests that patients with worse outcomes are apparent in the earlier stages of illness, rather than that the course of illness been a progressive one for the majority of patients. 98 This is supported by recent evidence indicating that treatment resistance in schizophrenia is present from illness onset for the majority who develop a treatment resistant course of illness. 99 We hypothesised that a greater proportion of cases of FEP would have recovered in recent years. However, similar to earlier reviews in multi episode patients (and in contrast to our findings in relation to remission rates), we did not identify that recovery rates were increasing over time. 5, 8, 9 In fact, we identified a significantly reduced pooled recovery rate for studies conducted from 1997-2016 (32%) compared to the pooled recovery rate of 45% for studies conducted from 1976-1996.
This finding in a FEP population indicates that thus far the dedicated and intensive specialist care provided for FEP patients over the past two decades has not resulted in improved recovery rates, even though remission rates were improved over the past two decades.
Knowledge of factors associated with increased recovery in FEP can help identify individuals in need of more robust interventions. However, we found few moderators of recovery in our meta-analysis. White ethnicity was associated with increased recovery, whereas Asian ethnicity was associated with lower recovery rates. Higher dropout rates moderated lower recovery, potentially indicative of a selection bias, in that those who are well, and are no longer in contact with mental health services may be disproportionately lost to follow up, thus impacting on the recovery rate.
Duration of Untreated Psychosis
A longer DUP was not a moderator of remission or recovery rates. This was a secondary outcome measure in our study, but despite that our findings are contrary to previous meta-analyses, which found that a shorter duration of untreated psychosis is associated with better outcomes. 100 While this finding is unexpected, it is important to highlight that we did not design our study to identify all FEP studies which have investigated DUP in relation to outcomes. Further, we did not screen studies for inclusion based on definitions of DUP, potentially introducing methodological variation, and confounding the finding. It may also be probable that patients with a longer DUP may be more likely to be lost to follow up, something which we did not control for. However, we included nine remission studies reporting on associations between mean duration of DUP and remission, similar to the ten studies included in a 2014 systematic review and meta-correlation analysis, which identified a weak negative correlation between longer mean DUP and remission. 101
Strengths and Limitations
While this is the first meta-analysis of remission and recovery in FEP, including a large data set of 19,897 FEP patients, we acknowledge some limitations.
First, there was considerable methodological heterogeneity across studies.
Consequently, we encountered high levels of statistical heterogeneity, which is to be expected when meta-analysing observational data. 15 We followed best practice in conducting subgroup and meta regression analyses to explore potential sources of heterogeneity. However, the main results do not appear to be influenced by publication bias, and were largely unaltered after applying the trim-and-fill method.
Further, for remission there was little variability in the overall rates of remission by definition of remission, study type and method of assessment used. Though the different definitions of recovery can provide an inflated rate of recovery, we provided data relating to studies with the most stringent criteria for recovery with symptomatic and functional recovery for more than 2 years (with an identified recovery rate of 22%). We further provided a worst case scenario rate for remission and recovery, imputing these values based on the trial number of recruited patients, and assuming that all those lost to follow up would not have met criteria for remission or recovery.
Our findings therefore, offer valid measures of remission and recovery in FEP.
Second there was inadequate data on important confounders such as treatments given over the course of follow up, adherence with treatment, social functioning and symptom profile over the course of follow up, and lifestyle factors such as alcohol and substance use, precluding the meta analytic assessment of these factors as moderating or mediating variables. Future studies may wish to consider including data from intervention studies in FEP, to assess the influence of specific treatments, and adherence to treatment on remission and recovery rates in FEP. 102 Third, data for this meta-analysis was extracted from baseline and follow up points from the individual studies, with limited information available in individual studies for the period during the follow up.
Fourth, while remission and recovery rates are provided at study endpoint, no data is available on those who met, and sustained criteria for remission or recovery for the entire duration of follow up, nor at what time point individuals met criteria for remission or recovery. The absence of such data does not allow for a more detailed description of illness trajectory. However, we have been able to delineate the effects of duration of study follow up on remission and recovery.
Fifth, while we identified studies from six regions of the world, there was marked variability in the number of studies from each region, with the majority of studies conducted in North America and Europe. In relation to the higher rate of recovery identified in North America compared to other regions, we cannot rule out confounding variables relating to differences in the types of patients with FEP who were enrolled in North America compared to other regions, and other service level confounds which may have existed between regions. However, our finding of lower remission rates in Europe is consistent with findings from the prospective W-SOHO study on the outcome for multi-episode schizophrenia in an out-patient setting. 103 Finally, consideration for the introduction of sampling bias due to the variability at the point of recruitment to FEP studies is required. Some may recover quickly from a FEP and not wish to participate, others may be severely unwell and unable to consent to participate, while community based FEP studies may be unable to recruit patients with more chaotic presentations.
Conclusions
This is the first meta-analysis of remission and recovery rates, and moderators of these outcomes, in people with FEP, and the first meta-analysis pooling and comparing all available data across patients with FEP, FES and first episode affective psychosis. We provide evidence of higher than expected rates for remission and recovery in FEP. We confirm that recovery rates stabilise after the first two years of illness, suggesting that psychosis is not a progressive deteriorating illness state.
While remission rates have improved over time, rates of recovery have not done so, potentially indicating that specialised FEP services in their current incarnation have not provided improved longer term recovery rates.
Our study highlights a better long term prognosis in FEP and FES, and a more positive outlook for people diagnosed with FEP and FES, than has been suggested by previous studies, which included patients with multi episode schizophrenia.
